Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease

NCT06822517 is registered in ClinicalTrials.gov with Ventus Therapeutics U.S., Inc. as lead sponsor.

NCT NCT06822517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06822517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease
Lead sponsor
Ventus Therapeutics U.S., Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
March 5, 2025
Completion date
October 9, 2025
Enrollment
29 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease